Illumina (NASDAQ:ILMN) Stock Price Expected to Rise, Guggenheim Analyst Says

Illumina (NASDAQ:ILMN) had its price objective lifted by equities research analysts at Guggenheim from $170.00 to $180.00 in a note issued to investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the life sciences company’s stock. Guggenheim’s price objective indicates a potential upside of 10.46% from the company’s current price.

Several other analysts have also recently commented on the company. Barclays boosted their price target on Illumina from $110.00 to $122.00 and gave the stock an “underweight” rating in a research report on Friday, May 1st. Citigroup boosted their price target on Illumina from $80.00 to $95.00 and gave the stock a “sell” rating in a research report on Monday, May 4th. Wall Street Zen cut Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Piper Sandler dropped their price target on Illumina from $195.00 to $170.00 and set an “overweight” rating for the company in a research report on Monday, February 9th. Finally, JPMorgan Chase & Co. upped their target price on Illumina from $120.00 to $125.00 and gave the company a “neutral” rating in a report on Friday, May 1st. Seven analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Illumina currently has a consensus rating of “Hold” and a consensus target price of $138.38.

Illumina Price Performance

Shares of ILMN opened at $162.96 on Monday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.36 and a current ratio of 1.75. Illumina has a one year low of $78.79 and a one year high of $165.37. The stock has a market capitalization of $24.66 billion, a price-to-earnings ratio of 29.63, a PEG ratio of 2.70 and a beta of 1.50. The stock has a 50 day moving average price of $133.73 and a 200 day moving average price of $132.09.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.05 by $0.10. Illumina had a return on equity of 31.01% and a net margin of 19.42%.The firm had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the previous year, the business earned $0.97 earnings per share. The firm’s revenue for the quarter was up 4.8% on a year-over-year basis. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts forecast that Illumina will post 5.2 earnings per share for the current fiscal year.

Insider Buying and Selling at Illumina

In other Illumina news, Director Keith A. Meister sold 104,393 shares of the company’s stock in a transaction dated Thursday, May 14th. The shares were sold at an average price of $145.34, for a total value of $15,172,478.62. Following the transaction, the director owned 3,500,048 shares of the company’s stock, valued at $508,696,976.32. This represents a 2.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Christensen Jakob Wedel sold 700 shares of the stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $139.04, for a total transaction of $97,328.00. Following the transaction, the senior vice president directly owned 15,056 shares of the company’s stock, valued at approximately $2,093,386.24. This trade represents a 4.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 330,160 shares of company stock valued at $48,028,308. 2.90% of the stock is owned by company insiders.

Institutional Investors Weigh In On Illumina

Institutional investors and hedge funds have recently made changes to their positions in the stock. Elyxium Wealth LLC purchased a new stake in shares of Illumina in the 4th quarter valued at approximately $25,000. Creative Capital Management Investments LLC raised its stake in shares of Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock valued at $26,000 after acquiring an additional 120 shares during the period. Board of the Pension Protection Fund purchased a new stake in shares of Illumina in the 4th quarter valued at approximately $26,000. TD Waterhouse Canada Inc. purchased a new stake in shares of Illumina in the 4th quarter valued at approximately $26,000. Finally, Laurel Wealth Advisors LLC purchased a new stake in shares of Illumina in the 4th quarter valued at approximately $26,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.